No Prescription |
 |
 | ||
|
Melanocyl Uvadex |
|
| ||
No Prescription » Prescription Drugs 10 » Melanocyl Uvadex Medical Information: This medication is used along with controlled ultraviolet light (UVA) to help control severe psoriasis. Methoxsalen belongs to a class of drugs known as psoralen photosensitizers. It works by making certain parts of the skin more sensitive to UVA light causing a skin reaction that helps to shrink psoriasis plaques. Buy Melanocyl Uvadex and other Prescription Drugs 10 products online at Medstore. Buy Online at Medstore - Click Here!
About Melanocyl Uvadex: Product Type: Prescription Drugs 10 Melanocyl ( Uvadex Oxsoralen-Ultra Generic Methoxsalen ) Melanocyl (Uvadex Oxsoralen-Ultra Generic Methoxsalen) Uvadex Oxsoralen-Ultra Generic Methoxsalen 10mg Uvadex Oxsoralen-Ultra Generic Methoxsalen Melanocyl
View more Prescription Drugs 10 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
